New insider activity at Cencora ( (COR) ) has taken place on February 24, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cencora’s President & CEO Robert Mauch has executed a notable insider transaction, selling 3,762 shares of Cencora stock in a move valued at $1,350,332. This sale by the company’s top executive may draw attention from investors monitoring insider activity and leadership confidence in the company’s future performance.
Recent Updates on COR stock
Cencora shares reacted to its upbeat Q1 report and guidance hike, as the company posted solid revenue and faster-growing operating income, driven by U.S. specialty distribution, GLP‑1 demand, and contributions from MSO assets like OneOncology and RCA, despite seasonal cash outflows and higher interest expense. Morgan Stanley raised its outlook on the stock mainly because Cencora has cemented a leading specialty MSO position via the OneOncology deal, is exploring divestitures of non-core assets to optimize the portfolio, and is expected to see an international earnings recovery by 2026 supported by World Courier.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Neutral.
The score is driven primarily by solid financial execution and cash generation but is held back by balance-sheet leverage and very thin margin structure. The earnings outlook is a clear positive with raised FY2026 revenue and operating income guidance, while technicals are supportive. Valuation is the main constraint given the high P/E and low dividend yield.
To see Spark’s full report on COR stock, click here.
More about Cencora
YTD Price Performance: 6.51%
Average Trading Volume: 1,368,797
Technical Sentiment Signal: Buy
Current Market Cap: $70.08B